September 28, 2023 11:01 AM EDT
News Briefing

Im­muno­van­t's $450M; On­copep­tides re­assess­es Pepax­ti strat­e­gy in Eu­rope; Ake­bia re­sub­mits kid­ney drug

Kyle LaHucik

Senior Reporter

Katherine Lewin

News Reporter

Jaimy Lee

Deputy Editor

Im­muno­vant goes for $450M: Im­muno­vant’s ear­ly-stage au­toim­mune da­ta will lead to a $450 mil­lion haul for the New York biotech, about …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times